PTPN13 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL458603	1.00	3/20
SCHEMBL3954523	0.65	2/20
SCHEMBL3975261	0.55	2/20
SCHEMBL19852	0.55	2/20
SCHEMBL2599394	0.51	2/20
SCHEMBL3964132	0.48	2/20
SCHEMBL720266	0.48	2/20
SCHEMBL867392	0.47	2/20
SCHEMBL3769269	0.47	2/20
SCHEMBL1384022	0.47	2/20
SCHEMBL1650266	0.45	2/20
SCHEMBL899006	0.44	2/20
SCHEMBL36613	0.44	2/20
SCHEMBL2255249	0.44	2/20
SCHEMBL2260906	0.44	2/20
SCHEMBL2747406	0.43	2/20
SCHEMBL2805577	0.43	2/20
Ethylene (SCHEMBL707063)	0.38	2/20
SCHEMBL1896550	0.38	2/20
SCHEMBL2599178	1.00	1/20

Clinical trials — most relevant to PTPN13 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC	PHASE2/PHASE3	NOT_YET_RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	PHASE2	COMPLETED
Immunoregulatory Therapy for 2019-nCoV	PHASE2	UNKNOWN
Leniolisib for Immune Dysregulation in PIDs	PHASE2	ACTIVE_NOT_RECRUITING
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme	PHASE2	UNKNOWN
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer	PHASE2	RECRUITING
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors	PHASE1	RECRUITING
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors	PHASE1	UNKNOWN
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
Resistance to Immunotherapy in Gastric Cancer	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
rT3 and Inflammation in Hashimoto's Thyroiditis	nan	COMPLETED
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus?	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
The Role of Autoantibodies Against G-protein Coupled Receptors in Obesity	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PTPN13 binder may also engage these)

Protein	Name	Similarity
Q64512	—	1.000	Q64512 →
Q60610	—	0.997	Q60610 →
Q1LYM3	—	0.996	Q1LYM3 →
Q9DDT2	—	0.996	Q9DDT2 →
A2AD83	—	0.996	A2AD83 →
Q6ZUT3	—	0.996	Q6ZUT3 →
Q6DJR2	—	0.996	Q6DJR2 →
Q5JCS6	—	0.995	Q5JCS6 →
Q9Z1T6	—	0.995	Q9Z1T6 →
D4AEC2	—	0.995	D4AEC2 →
Q9BXL7	—	0.995	Q9BXL7 →
Q9D684	—	0.994	Q9D684 →
Q5RAY1	—	0.994	Q5RAY1 →
Q5PQS3	—	0.994	Q5PQS3 →
Q14D04	—	0.994	Q14D04 →
Q08AX9	—	0.994	Q08AX9 →
Q8C0T5	—	0.994	Q8C0T5 →
A6QP06	—	0.994	A6QP06 →
Q9FY74	—	0.994	Q9FY74 →
P61406	—	0.994	P61406 →
A8E7C5	—	0.994	A8E7C5 →
G5EFD2	—	0.994	G5EFD2 →
Q6ING4	—	0.994	Q6ING4 →
O43166	—	0.993	O43166 →
Q92539	—	0.993	Q92539 →
Q9Y2H2	—	0.993	Q9Y2H2 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.993	landscape →
Q6ZPS6	—	0.993	Q6ZPS6 →
Q17QK1	—	0.993	Q17QK1 →
A4IIJ3	—	0.993	A4IIJ3 →